首页|达格列净、西格列汀分别联合二甲双胍在肥胖型2型糖尿病患者糖脂代谢及炎症反应中的影响比较

达格列净、西格列汀分别联合二甲双胍在肥胖型2型糖尿病患者糖脂代谢及炎症反应中的影响比较

扫码查看
目的 探究达格列净、西格列汀分别联合二甲双胍对肥胖型 2 型糖尿病患者糖脂代谢及炎症反应的影响。方法 选取儋州市人民医院 2019 年 1 月至 2022 年 1 月 120 例肥胖型 2 型糖尿病患者,分为观察组和对照组,分别采用达格列净联合二甲双胍、西格列汀联合二甲双胍治疗。对比观察组和对照组患者疗效以及治疗前后糖脂代谢指标和血清炎症因子变化情况。结果 治疗后观察组患者的疗效(96。67%)高于对照组患者(83。33%),差异有统计学意义(P<0。05)。治疗前观察组和对照组患者的糖脂代谢指标和血清炎症因子水平差异均无统计学意义(P>0。05)。治疗后观察组和对照组患者糖代谢指标比较,空腹血糖(FPG)、餐后 2 h血糖(2 hPBG)、糖化血红蛋白(HbA1c)水平均下降(P<0。05),且观察组患者FPG、2 hPBG、HbA1c低于对照组患者(P<0。05)。治疗后对照组和观察组患者脂代谢指标总胆固醇(TC)、三酰甘油(TG)、低密度脂蛋白胆固醇(LDL-C)均下降(P<0。05),高密度脂蛋白胆固醇(HDL-C)水平上升,且观察组TC、TG和LDL-C低于对照组,HDL-C高于对照组(P<0。05)。治疗后对照组和观察组患者的血清炎症因子C反应蛋白(hs-CRP)、白细胞介素-6(IL-6)、肿瘤坏死因子α(TNF-α)水平均下降,且观察组低于同时点的对照组(P<0。05)。结论 肥胖型 2 型糖尿病患者无论是采用达格列净联合二甲双胍治疗还是采用西格列汀联合二甲双胍治疗均有效,但达格列净联合二甲双胍的治疗效果更好,可以有效改善患者糖脂代谢,降低患者炎症因子水平。
Effects of dapagliflozin and sitagliptin combined with metformin on glucose and lipid metabolism and inflammatory reaction in obese type 2 diabetes patients
Objective To compare the effects of dapagliflozin and sitagliptin combined with metformin on glucose and lipid metabolism and inflammatory reaction in obese type 2 diabetes patients.Methods A total of 120 obese type 2 diabetes patients treated in Danzhou People's Hospital from January 2019 to January 2022 were divided into observation group(dapagliflozin+metformin)and control group(sitagliptin+metformin).The indexes of glucose and lipid metabolism and serum inflammatory factors were recorded before and after treatment.The curative effect was compared between the two groups.Results The curative effect of the observation group was significantly higher than that of the control group(96.67%vs.83.33%,P<0.05).There were no significant differences in the indexes of glucose and lipid metabolism or the levels of serum inflammatory factors between the two groups before treatment(all P>0.05).Fasting blood glucose(FBG),2-hour postprandial blood glucose(2 hPBG),glycosylated hemoglobin(HbA1c),total cholesterol(TC),triglyceride(TG),low-density lipoprotein cholesterol(LDL-C),interleukin-6(IL-6),tumor necrosis factor α(TNF-α)and C-reactive protein(CRP)were significantly decreased after treatment in both groups,and high-density lipoprotein cholesterol(HDL-C)was significantly increased(all P<0.05).The observation group had lower levels of FBG,2 hPBG,HbA1c,TC,TG,LDL-C,IL-6,TNF-α and CRP and higher level of HDL-C than control group after treatment(all P<0.05).Conclusion Both dapagliflozin and sitagliptin combined with metformin are effective for the treatment of obese type 2 diabetes.But the combined use of dapagliflozin and metformin is more effective;it can effectively improve the glucose and lipid metabolism and reduce the level of inflammatory factors,making it worthy of clinical promotion.

ObesityType 2 diabetesDapagliflozinSitagliptinMetforminGlucose and lipid metabolismInflammatory reaction

李珍、吴飞、张梅、谢桃梅

展开 >

571700 海南 儋州,儋州市人民医院内分泌代谢科

肥胖 2型糖尿病 达格列净 西格列汀 二甲双胍 糖脂代谢 炎症反应

海南省卫生健康行业科研项目

22A200155

2024

海军医学杂志
海军医学研究所

海军医学杂志

CSTPCD
影响因子:0.518
ISSN:1009-0754
年,卷(期):2024.45(9)